GO
Loading...

Merck & Co Inc

More

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • Cramer Remix: Party with these rock star stocks Thursday, 8 Jan 2015 | 7:15 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer on the players that could keep tearing it up in 2015.

  • S&P 500 records longest loss streak since late 2013 Tuesday, 6 Jan 2015 | 4:37 PM ET
    Traders work on the floor of the New York Stock Exchange, Oct. 29, 2014.

    Stocks fell Tuesday as investors fretted the implications of crude's failure to find a floor.

  • J&J and Bavarian Nordic start Ebola vaccine tests Tuesday, 6 Jan 2015 | 5:03 AM ET
    Amanda Smith, graduate student from the University of Utah, holds a container with test material in a sealed lab with a non-infective forum of the Ebola virus to help discover a drug that is effective against a part of Ebola that is vulnerable to drugs, on October 14, 2014 in Salt Lake City, Utah.

    Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic.

  • Jan 5- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday. WBB Securities' Steve...

  • Early Movers: CAT, INTC, PBPB, BSX, CEMP & more Monday, 5 Jan 2015 | 8:52 AM ET

    Companies making headlines ahead the bell Monday:

  • Jan 5- Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Data showed solithromycin actually outperformed moxifloxacin by a slight margin, Cempra said on Sunday. North Carolina- based Cempra is also evaluating an intravenous formulation of...

  • FDA approves 41 novel medicines in 2014 vs 27 in 2013. LONDON, Jan 1- U.S. drug approvals in 2014 hit their highest level in 18 years and recommendations in Europe also came at a rapid rate, driven by expensive new treatments for cancer and rare diseases. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research approved 41 novel medicines in...

  • Stocks extend holiday cheer: S&P, Dow end at records Friday, 26 Dec 2014 | 4:00 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Stocks rose in light volume on Friday, with the Dow and S&P 500 closing at records.

  • Dec 23- The U.S. Department of Health and Human Services awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines. Under a $30 million contract, NewLink's unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • Dec 19- Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs. Zerbaxa is the fourth new antibacterial drug approved by the FDA this year. The agency approved Actavis Plc's Dalvance in...

  • Lawyers cash in on favors from state prosecutors Friday, 19 Dec 2014 | 10:54 AM ET
    Gary King speaks during the Democratic Party for New Mexico 2014 Governor Forum in Albuquerque, N.M., May, 2014.

    The partnership is part of an industry pairing plaintiffs' lawyers with state attorneys general to sue companies. The NYT reports.

  • *Shares in GSK partner Agenus jump 10 percent. LONDON, Dec 18- An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost. The data suggests the British company's new shot could be a strong competitor for Merck& Co's established vaccine...

  • LONDON, Dec 18- An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Merck& Co already sells another...

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • NEW YORK/ WASHINGTON, Dec 11- U.S. prosecutors, already smarting from a appeals court ruling that weakens their ability to crack down on future insider trading, on Thursday faced widening fallout from the decision as some existing cases threatened to unravel. Lawyers for some defendants hinted they might seek to withdraw guilty pleas, and a Manhattan federal...